NT4-TAT-6×His-VHLβ结构域肾癌抑制融合肽cDNA克隆的构建

Construction and identification of recombinant plasmid expressing NT4-TAT-6×His-VHLβ fusion peptide

目的构建VHL蛋白(von Hippel-Lindau protein,pVHL)β结构域肾癌抑制融合肽cDNA,并将其应用于肾癌的微基因治疗。方法分别设计合成pVHLβ结构域104-123短肽cDNA的正向和反向引物以及编码TAT-6×His cD-NA的正、反向引物,使用互为引物模板PCR方法,扩增获得具有NaeI/Eco72I酶识别位点的TAT-6×His cDNA片段和具有Eco72I/BamH I酶识别位点的VHLβ抑制肽cDNA片段,将两个片段分别克隆到pGEM-T easy中,使用双脱氧终止法测序,通过DNASIS软件分析同数据库资料一致性和编码的氨基酸序列。用NaeI和BamH I双酶切获取的TAT-6×His-VHLβcDNA片段插入到具有NT4信号肽的pBV220载体中,构建了pBV220-NT4-TAT-6×His-VHLβ质粒。结果经DNA测序证实,获得了编码TAT-6×His cDNA片段和编码VHLβ抑制肽的cDNA片段,分析证实核酸序列和推导的氨基酸同数据库资料一致。重组质粒pBV220-NT4-TAT-6×His-VHLβ酶切图谱证实已将NT4-TAT-6×His-VHLβ融合肽cDNA克隆到pBV220原核表达载体中。结论成功扩增了编码TAT膜渗透肽和6×His标签肽以及VHL抑癌基因β结构域肾癌抑制肽的cDNA片段,构建了具有NT4信号肽的TAT-6×His-VHLβ融合肽cDNA。

Objective The specific amino acid sequence(104-123) in β-domain of pVHL is sufficient to inhibit the growth and invasion of renal cell carcinoma(RCC).To express this peptide for a gene therapy of RCC by using minigene,we constructed and identified the recombinant plasmid expression box,including NT4 signal peptide,tag and cell penetrating peptides.Methods By means of asymmetrical primer/template,fragments encoding β-domain of pVHL(the VHL gene product) and TAT-6×His were gained,which included Nae I/Eco72I a...